Literature DB >> 18771712

Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression.

J A Benítez1, L Arregui, G Cabrera, J Segovia.   

Abstract

Glioblastoma is the most frequent primary brain tumor, and for which standard therapies have not significantly increased the survival of patients. Recently, chromatin alterations have been linked to the pathogenesis of cancer, and drugs that modify chromatin structure, such as inhibitors of histone deacetylases (iHDAC), are now considered as a valuable strategy for the treatment of cancer. For instance, valproic acid (VPA), an iHDAC originally used for the treatment of bipolar disorders and epilepsy, is now being used in cancer therapy. In this work we show that VPA induces morphological changes in murine astrocytoma C6 cells, which are associated with inhibition of cell proliferation, growth arrest, decreased cell migration, cell death and histone 4 hyperacetylation. VPA-treated cells extended processes with characteristics similar to the structure of a growth cone, and we also observed both a down-regulation of glial protein markers and increased expression of a neuronal specific protein after VPA treatment. Finally, there is an increase in the expression of a reporter transgene driven by a neuronal-specific promoter and a decrease of gene expression using a glial specific promoter in VPA-treated cells. These results indicate that VPA induces a specific differentiation of C6 cells toward a neuronal-like phenotype. The present data highlight the importance of epigenetic phenomena in the development and differentiation of the nervous system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771712     DOI: 10.1016/j.neuroscience.2008.07.065

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

2.  Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.

Authors:  Carlos Gustavo Garcia; Suzana Assad Kahn; Luiz Henrique Medeiros Geraldo; Igor Romano; Ivan Domith; Deborah Christinne Lima E Silva; Fernando Dos Santos Assunção; Marcos José Ferreira; Camila Cabral Portugal; Jorge Marcondes de Souza; Luciana Ferreira Romão; Annibal Duarte Pereira Netto; Flávia Regina Souza Lima; Marcelo Cossenza
Journal:  Mol Neurobiol       Date:  2018-01-19       Impact factor: 5.590

Review 3.  Deregulated proliferation and differentiation in brain tumors.

Authors:  Fredrik J Swartling; Matko Čančer; Aaron Frantz; Holger Weishaupt; Anders I Persson
Journal:  Cell Tissue Res       Date:  2014-11-23       Impact factor: 5.249

4.  Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.

Authors:  Sharon Berendsen; Elselien Frijlink; Jèrôme Kroonen; Wim G M Spliet; Wim van Hecke; Tatjana Seute; Tom J Snijders; Pierre A Robe
Journal:  Neurooncol Adv       Date:  2019-11-12

5.  Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.

Authors:  Yong Zhou; Ying Xu; Han Wang; Junjie Niu; Huaying Hou; Yuhua Jiang
Journal:  Oncol Lett       Date:  2013-11-07       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.